Free Trial

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$8.00 +0.58 (+7.82%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$8.15 +0.15 (+1.94%)
As of 07:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Key Stats

Today's Range
$7.37
$8.78
50-Day Range
$5.47
$8.00
52-Week Range
$2.36
$8.78
Volume
9.49 million shs
Average Volume
1.42 million shs
Market Capitalization
$974.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.11
Consensus Rating
Buy

Company Overview

Trevi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

TRVI MarketRank™: 

Trevi Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 509th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Trevi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trevi Therapeutics is -19.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trevi Therapeutics is -19.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Trevi Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.21% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.21% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Trevi Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 5 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 9 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVI Stock News Headlines

Trevi Therapeutics (NASDAQ:TRVI) Now Covered by Morgan Stanley
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
B. Riley Increases Earnings Estimates for Trevi Therapeutics
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $4.12 at the beginning of the year. Since then, TRVI stock has increased by 94.2% and is now trading at $8.00.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.
Read the conference call transcript
.

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional shareholders of Trevi Therapeutics include Rubric Capital Management LP (7.01%), Vivo Capital LLC (3.69%), Alliancebernstein L.P. (3.52%) and Octagon Capital Advisors LP (3.02%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends
.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRVI
CIK
1563880
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$27.00
Low Price Target
$7.00
Potential Upside/Downside
+151.4%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.44%
Return on Assets
-38.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.42
Quick Ratio
22.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.63 per share
Price / Book
4.91

Miscellaneous

Outstanding Shares
121,780,000
Free Float
99,492,000
Market Cap
$974.24 million
Optionable
Optionable
Beta
0.58

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners